#None #medical technology #ENDYMED #Shanghai Haohai

ENDYMED's Strategic Merger with Shanghai Haohai

In a significant development within the medical technology landscape, ENDYMED Ltd has announced the completion of its full merger with its majority shareholder, Shanghai Haohai Biological Technology Co., Ltd. This strategic consolidation is poised to not only fortify ENDYMED's presence in the competitive Chinese market but also to enhance its global reach, leading to improved operational efficiency and market competitiveness.

The merger, which symbolizes a pivotal consolidation of resources and capabilities, will empower ENDYMED to streamline various processes, allowing it to better serve its clientele worldwide. By integrating its operation with Haohai, ENDYMED can harness expanded resources and strategic flexibility that significantly enhances its decision-making on an international scale.

"This merger marks a transformative step for ENDYMED, enabling us to better serve our customers globally while maintaining strong local market expertise," said Yossi Bar-On, CEO of ENDYMED. This statement reflects the company’s commitment to delivering innovative and effective solutions for skin rejuvenation and aesthetic treatments.

Dr. Hou, Chairman of HAOHAI and ENDYMED, added, "This strategic move not only strengthens our global presence but also enhances the value we bring to our customers." The merger aims to drive innovation and operational excellence in both companies, setting a solid groundwork for sustainable growth in the years to come.

About Haohai

Founded on April 30, 2015, Haohai operates as an innovative technology enterprise emphasizing biomedical material technology and genetic engineering. It specializes in the research, development, manufacture, and sales of advanced medical devices and pharmaceuticals. Moreover, it became notable as the first biopharmaceutical company in China listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange STAR Market. Haohai remains committed to providing leading-edge products across various medical specialties, including ophthalmology, aesthetics, orthopedics, and surgical applications.

About ENDYMED

Established to pioneer advancements in energy-based aesthetic solutions, ENDYMED is recognized for its FDA-cleared 3DEEP® RF technology. This innovative system is among the most clinically validated in the industry and underpins a range of professional and home-use devices designed to cater to the needs of clinicians and their patients. ENDYMED aims to reshape the future of non-invasive aesthetic treatments by combining rigorous scientific methods with a focus on patient safety and superior outcomes.

The merger with Haohai not only represents a momentous achievement for ENDYMED but also positions the company prominently on the global stage, enhancing its capabilities to deliver top-notch solutions in aesthetic medicine effectively. By collaborating with its new partner, ENDYMED is positioned to thrive amidst the evolving dynamics of the healthcare and aesthetics marketplaces, continually meeting the needs of informed consumers and professionals.

As ENDYMED embarks on this promising journey post-merger, it remains dedicated to fostering innovation, enhancing customer satisfaction, and driving growth within the aesthetic treatment industry on a worldwide scale.